Navigation Links
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Date:5/13/2008

the U.S. Food and Drug Administration (FDA), demonstrated the following key results for XIENCE V at two years:

-- A 45 percent reduction in the risk of major adverse cardiac events

(MACE) compared to TAXUS (7.3 percent for XIENCE V vs. 12.8 percent for

TAXUS, p-value=0.004)*. MACE is an important composite clinical measure

of safety and efficacy outcomes for patients, defined as cardiac death,

heart attack (MI), or ischemia-driven target lesion revascularization

(TLR driven by lack of blood supply).

-- A 32 percent reduction in the risk of Target Vessel Failure (TVF,

cardiac events related to the treated vessel) compared to TAXUS

(10.7 percent for XIENCE V vs. 15.4 percent for TAXUS, p-value=0.04)*.

TVF is a composite clinical measure of safety and efficacy outcomes

defined as cardiac death, heart attack (myocardial infarction or MI) or

target vessel revascularization (TVR).

-- A 40 percent reduction in the risk of ischemia-driven target lesion

revascularization (ID-TLR) as compared to TAXUS (4.6 percent for

XIENCE V vs. 7.5 percent for TAXUS, p-value=0.07)*.

-- Low rates of stent thrombosis between one and two years, defined as

very late stent thrombosis, per Academic Research Consortium (ARC)

definition of definite/probable stent thrombosis (0.3 percent for

XIENCE V and 1.0 percent for TAXUS) and per the SPIRIT III protocol

(0.2 percent for XIENCE V and 1.0 percent for TAXUS). The ARC

definitions of stent thrombosis were developed to eliminate variability

in the definitions across various drug eluting stent trials.

"From these results, it is clear that XIENCE V can deliver sustained benefits to patients over the long term," said John M. Capek, Ph.D., executive vice president, Medical Products, Abbott. "We continue to be pleased with the way XIENCE V is performing, w
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
2. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
5. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
6. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
7. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
8. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
9. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
11. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  CARsgen, a leader in the development of Chimeric ... variety of cancers, today announced the completion of a ... China -based healthcare private equity fund.   ... development of new therapeutics for liver, lung, stomach and ... Shanghai Renji Hospital, the company plans to initiate clinical ...
(Date:11/26/2014)... Nov. 26, 2014 The medical magnetic ... rate of 4%, with world market revenues for ... MRI and other types of medical imaging have ... of numerous medical conditions in children and adults, ... Kalorama,s report, Medical Imaging Markets , analyzes ...
(Date:11/26/2014)... DALLAS , November 25, 2014 ... Surgical Instruments Market by Power Source (Electric, Battery, ... Console, Cables, Blade, Burr, Cart), by Application (Orthopedic, ... 2019" published by MarketsandMarkets, the global Powered Surgical Instruments ... to $1.6 Billion in 2014 and is expected ...
Breaking Medicine Technology:CARsgen Completes Series A Financing 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4
(Date:11/26/2014)... Bunion Bootie, the newest and best ... early celebration of the early holiday shopping season. Starting ... the promotional price of $29.95 each (normally $33.95 ea). ... any automatic discounts applied when buying more than one ... for complete details. It’s simple: purchasing more Bunion Booties ...
(Date:11/26/2014)... November 26, 2014 Louisiana Back ... and specialists in minimally invasive spine surgery, announces ... into the rapidly growing provider network of orthopedic ... addition coincides with the network’s continuing success providing ... for Louisiana residents who are suffering from orthopedic ...
(Date:11/26/2014)... 2014 Sonoran Vein and Endovascular ... the Distinguished Preceptorship Award from The American ... in the advancement of nurse practitioners. The Distinguished ... who had made a significant contribution toward increasing ... Association of Nurse Practitioners (AANP) is the largest ...
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Youngsters who enter puberty ... study suggests. Early puberty was linked with a ... self-image and high anxiety levels, according to the researchers. ... as conflict with family and peers, and having friends ... found. Although the study found an association between ...
(Date:11/26/2014)... -- Teens prescribed anti-anxiety or sleep medications are ... other teens, a new study warns. The ... assessments on teenagers before prescribing these drugs to ... don,t realize the abuse potential," said lead researcher ... Michigan School of Nursing. "These drugs produce highly ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie Temporarily Lowering Prices for Holiday Shopping, Starting Today! 2Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2Health News:Sonoran Nurse Receives Distinguished Preceptorship Award from The American Association of Nurse Practitioners 2Health News:Early Puberty Linked to Increased Risk of Depression in Teens 2Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2
... 19 Healthcare,Technologies Ltd. (NASDAQ: HCTL ), announced ... scheduled for September 30,2007, will be held on December ... Arnon & Co., 1 Azrieli Center, Round Tower, 47th ... be asked to approve the previously,announced Asset Purchase Agreement ...
... may lower sperm count" do not tell the whole ... from the Harvard,School of Public Health in Boston presented ... was based on recollected intake,of soyfoods and not on ... issues, thus I feel the results should be viewed ...
... 18 West Pharmaceutical,Services, Inc. (NYSE: WST ... that it has decided to discontinue marketing the,Exubera ... the,Company,s customer, Nektar Therapeutics, Inc. The Company,s Tech ... Exubera inhalation device for Nektar. "We were ...
... Blocks inflammatory activity of two immune system molecules, researchers ... new twist on an old theory of drug treatment ... trial, a California company reports. , The idea is ... believed to play a major role in asthma by ...
... Republican Whip,Roy Blunt (Mo.) issued the following statement today ... the State,Children,s Health Insurance Program (SCHIP) to children from ... "Today,s vote brings to a close what,s been a ... their energy to scoring,political points, and none of it ...
... 18 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: QLTI;,TSX: QLT) ... of,privately held ForSight Newco II, Inc. Through this ... to commercialize,ForSight Newco II,s proprietary ocular punctal plug ... development efforts in this program. "We are ...
Cached Medicine News:Health News:Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction 2Health News:Healthcare Technologies Announces New Date for the Shareholders Meeting to Approve the Nexgen Biofuels Transaction 3Health News:Real Men Eat Soy: The Truth about Soy and Sperm Count 2Health News:West Pharmaceutical Services Issues Statement on Exubera 2Health News:West Pharmaceutical Services Issues Statement on Exubera 3Health News:West Pharmaceutical Services Issues Statement on Exubera 4Health News:New Drug Eases Asthma Symptoms 2Health News:New Drug Eases Asthma Symptoms 3Health News:QLT Completes Acquisition of ForSight Newco II, Inc. 2Health News:QLT Completes Acquisition of ForSight Newco II, Inc. 3
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
An ideal choice for film photography. The new TRC-50FXC provides 35mm color and Polaroid capability....
Digital imaging for optical screening: Diabetes, glaucoma macular degeneration, and other retinal disease....
All welded construction for strength and durability. Choice of stainless steel or chrome plated models....
Medicine Products: